Laserfiche WebLink
<br />C-8 <br /> <br /> <br />c. The prescribing of the lowest effective dose of an Opioid, including but not <br />limited to third party reimbursement or payment for such prescription; <br />d. The limitation of initial prescriptions of Opioids to treat acute pain; <br />e. The prescribing and other means of distribution of naloxone to minimize the <br />risk of overdose, including but not limited to third party reimbursement or <br />payment for naloxone; <br />f. The use of urine testing before starting Opioid use and annual urine testing <br />when Opioids are prescribed, including but not limited to third party <br />reimbursement or payment for such testing; <br />g. Evidence-based treatment (such as using medication-assisted treatment with <br />buprenorphine or methadone in combination with behavioral therapies) for <br />OUD, including but not limited to third party reimbursement or payment for <br />such treatment; or <br />h. The implementation or use of Opioid drug disposal systems. <br />3. Janssen shall not Lobby against the enactment of any federal, state or local <br />legislative or regulatory provision expanding the operation or use of PDMPs, <br />including but not limited to provisions requiring Health Care Providers to review <br />PDMPs when Opioid use is initiated and with every prescription thereafter. <br />4. Notwithstanding the foregoing restrictions in subsections F.1-3, the following <br />conduct is not restricted: <br />a. Challenging the enforcement of or suing for declaratory or injunctive relief <br />with respect to legislation, rules, or regulations referred to in subsection F.1; <br />b. Communications made by Janssen in response to a statute, rule, regulation, or <br />order requiring such communication; <br />c. Communications by a Janssen representative appearing before a federal or <br />state legislative or administrative body, committee, or subcommittee as result <br />of a mandatory order or subpoena commanding that person to testify; <br />d. Responding, in a manner consistent with the Agreement, to an unsolicited <br />request for the input on the passage of legislation or the promulgation of any <br />rule or regulation when such request is submitted in writing specifically to <br />Janssen from a government entity directly involved in the passage of that <br />legislation or promulgation of that rule or regulation; or <br />e. Lobbying for or against provisions of legislation or regulation that address <br />other subjects in addition to those identified in subsections F.1-3, so long as <br />the company does not support specific portions of such legislation or